Equities research analysts forecast that Iqvia Holdings Inc (NYSE:IQV) will report earnings per share (EPS) of $1.39 for the current fiscal quarter, Zacks reports. Eleven analysts have provided estimates for Iqvia’s earnings. The lowest EPS estimate is $1.38 and the highest is $1.44. Iqvia posted earnings per share of $1.19 during the same quarter last year, which suggests a positive year over year growth rate of 16.8%. The company is scheduled to announce its next earnings report on Thursday, October 25th.

On average, analysts expect that Iqvia will report full-year earnings of $5.50 per share for the current fiscal year, with EPS estimates ranging from $5.45 to $5.56. For the next financial year, analysts forecast that the company will report earnings of $6.28 per share, with EPS estimates ranging from $6.17 to $6.35. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Iqvia.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 24th. The medical research company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.15. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The business had revenue of $2.57 billion during the quarter, compared to the consensus estimate of $2.50 billion. The company’s revenue was up 9.0% on a year-over-year basis.

Several equities analysts have issued reports on IQV shares. Morgan Stanley upped their price target on shares of Iqvia from $121.00 to $130.00 and gave the company an “overweight” rating in a research report on Wednesday, July 25th. Royal Bank of Canada restated a “buy” rating and issued a $129.00 price target on shares of Iqvia in a research report on Wednesday, July 25th. Robert W. Baird upped their price target on shares of Iqvia from $127.00 to $143.00 and gave the company an “outperform” rating in a research report on Wednesday, July 25th. JPMorgan Chase & Co. upped their price target on shares of Iqvia to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, July 25th. Finally, Zacks Investment Research upgraded shares of Iqvia from a “hold” rating to a “buy” rating and set a $111.00 price target for the company in a research report on Wednesday, July 4th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $124.44.

In other Iqvia news, Director Ronald A. Rittenmeyer sold 7,680 shares of the firm’s stock in a transaction on Thursday, July 26th. The shares were sold at an average price of $122.41, for a total value of $940,108.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Robert Parks sold 871 shares of the firm’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $124.34, for a total transaction of $108,300.14. The disclosure for this sale can be found here. Insiders sold 11,201,623 shares of company stock valued at $1,160,990,595 over the last 90 days. Corporate insiders own 6.00% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the business. Andra AP fonden lifted its stake in shares of Iqvia by 30.6% in the second quarter. Andra AP fonden now owns 33,300 shares of the medical research company’s stock valued at $3,324,000 after buying an additional 7,800 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of Iqvia by 2.0% in the second quarter. California Public Employees Retirement System now owns 361,884 shares of the medical research company’s stock valued at $36,123,000 after buying an additional 7,202 shares in the last quarter. Bridges Investment Management Inc. lifted its stake in shares of Iqvia by 16.1% in the second quarter. Bridges Investment Management Inc. now owns 35,013 shares of the medical research company’s stock valued at $3,495,000 after buying an additional 4,852 shares in the last quarter. Centaurus Financial Inc. lifted its stake in shares of Iqvia by 12.8% in the second quarter. Centaurus Financial Inc. now owns 12,357 shares of the medical research company’s stock valued at $1,233,000 after buying an additional 1,403 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Iqvia in the second quarter valued at $1,398,000. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

NYSE IQV traded down $0.75 on Tuesday, hitting $120.28. The company’s stock had a trading volume of 833,892 shares, compared to its average volume of 1,283,634. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.13 and a current ratio of 1.13. Iqvia has a 1-year low of $90.56 and a 1-year high of $125.35. The stock has a market cap of $24.54 billion, a P/E ratio of 27.59, a price-to-earnings-growth ratio of 1.95 and a beta of 0.72.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: What are the Different Types of Leveraged Buyouts?

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.